Zobrazeno 1 - 10
of 72
pro vyhledávání: '"35"'
Autor:
Danielle M. Friedrichsen, Janet R. Daling, Mariela C. Humphrey, Brian L. Strom, Nicola M. Suter, Jill A. McDonald, David R. Doody, Robert Spirtas, Polly A. Marchbanks, Ralph J. Coates, Ronald T. Burkman, Linda K. Weiss, Sandra A. Norman, Elaine A. Ostrander, Li Hsu, Jennifer Madeoy, Kathleen E. Malone, Dennis Deapen, Suzanne G. Folger, Michael S. Simon, Giske Ursin, Leslie Bernstein
Publikováno v:
Cancer research. 66(16)
Although well studied in families at high-risk, the roles of mutations in the BRCA1 and BRCA2 genes are poorly understood in breast cancers in the general population, particularly in Black women and in age groups outside of the very young. We examine
Autor:
J. Balmaña, J. Ferro, S. Gutierrez-Enríquez, M. Masas, N. Gadea, D. Fortuny, C. Saura, O. Díez
Publikováno v:
Cancer Research. 69:4072-4072
Background: Early onset breast cancer is part of the tumor spectrum in the Li-Fraumeni syndrome (MIM 151623), which is associated with germ-line mutations in the TP53 gene. The aim of the study is to determine the presence of inherited mutations in T
Autor:
Musa Mayer, Mary Beattie, Sara A. Hurvitz, Adam Brufsky, Bongin Yoo, Denise A. Yardley, Hope S. Rugo, Mohammad Jahanzeb, Sandra M. Swain, Peter A. Kaufman, Joyce O'Shaughnessy, Ginny Mason, Debu Tripathy, Melody A. Cobleigh
Publikováno v:
Cancer Research. 75:P3-07
Introduction The Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry (SystHERs) is a US-based prospective observational cohort study currently enrolling patients with HER2-positive metastatic breast cancer (MBC). It began in 2012 a
Autor:
A Horio, N Gondou, A Ushio, Naoto Kondo, Masataka Sawaki, Masaya Hattori, Takashi Fujita, Hiroji Iwata
Publikováno v:
Cancer Research. 72:P3-12
Background: Recent advances in chemotherapy have enabled to control the progression of metastases from breast cancer except for the brain, highlighting the symptoms associated with brain metastases. In addition, improvement in our understanding of br
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Publikováno v:
Cancer Research. 70:P2-06
Introduction: The incidence of breast cancer, the most common cancer in women, is very high in Western Countries and is increasing rapidly in the Third World. Yet, despite better screening, earlier diagnosis, and the development of new therapies, a c
Publikováno v:
Cancer Research. 81:PS2-12
Background Oncotype Dx Recurrence Score (ODX-RS) is a 21-gene assay used to predict recurrence in early stage breast cancer and guide chemotherapy decisions. Invasive lobular carcinomas (ILC) represent approximately 10-15% of all breast cancers. Many
Publikováno v:
Cancer Research. 80:P6-10
Background: Ductal carcinoma in situ (DCIS) is considered a non-obligate precursor of invasive breast cancer (IBC). It is estimated that 5-14% of women diagnosed with DCIS experience an ipsilateral IBC. Current clinical criteria do not discriminate w
Autor:
Hyo S. Han, Bruce A. Bach, Shannon Puhalla, David Maag, Hans Wildiers, Véronique Diéras, Dai Feng, Jean-Pierre M. Ayoub, Christine K. Ratajczak, Michael Friedlander, Bella Kaufman, Banu Arun
Publikováno v:
Cancer Research. 81:PS11-03
Background: Veliparib (Vel) is a potent PARP1/2 inhibitor with demonstrated antitumor activity when administered alone or combined with carboplatin and paclitaxel (C/P). The phase 3 randomized, double-blind, multicenter BROCADE3 study (NCT02163694) e
Autor:
Fumiaki Sato, Zhipeng Wang, Takayuki Ueno, Akira Myomoto, Satoko Takizawa, Feng Ling Pu, Norikazu Masuda, Yoshiki Mikami, Kazuharu Shimizu, Shigehira Saji, Masakazu Toi
Publikováno v:
Cancer Research. 73:1937-1937
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi